Table I.
Characteristics of patients enrolled in total therapy 2 (TT 2) according to protocol arm [with or without thalidomide (THAL)] and in total therapy 1 (TT1).
| Arm | ||||||
|---|---|---|---|---|---|---|
|
|
||||||
| Factor | TT1 | TT2 | P* | No THAL | THAL | P* |
| Age ≥65 years | 21/231 (9) | 136/668 (20) | <0.001 | 72/345 (21) | 64/323 (20) | 0.735 |
| Female | 88/231 (38) | 272/668 (41) | 0.483 | 135/345 (39) | 137/323 (42) | 0.388 |
| Caucasian | 206/231 (89) | 600/668 (90) | 0.782 | 308/345 (89) | 292/323 (90) | 0.630 |
| IgA isotype | 41/231 (18) | 161/668 (24) | 0.046 | 77/345 (22) | 84/323 (26) | 0.265 |
| Albumin <35 g/l | 62/231 (27) | 119/664 (18) | 0.004 | 59/343 (17) | 60/321 (19) | 0.617 |
| B2M ≥3.5 mg/l | 95/229 (41) | 243/668 (36) | 0.169 | 126/345 (37) | 117/323 (36) | 0.936 |
| Creatinine ≥176.8 μmol/l | 22/231 (10) | 62/654 (9) | 0.984 | 127/339 (37) | 136/319 (43) | 0.176 |
| CRP ≥8.0 mg/l | 70/223 (31) | 263/658 (40) | 0.022 | 98/344 (28) | 106/322 (33) | 0.215 |
| LDH >190 U/l | 49/230 (21) | 204/666 (31) | 0.007 | 37/339 (11) | 25/315 (8) | 0.194 |
| Hb <100 g/l | 78/231 (34) | 161/667 (24) | 0.004 | 80/345 (23) | 81/322 (25) | 0.553 |
| Cytogenetic abnormalities | 74/221 (33) | 197/661 (30) | 0.305 | 104/339 (31) | 93/322 (29) | 0.614 |
Values in parenthesis are in percentage.
*
From chi-square test.